Clinical Trial Update: AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating AZD1775 in advanced, refractory solid tumors with CCNE1 amplification has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Solid Neoplasm

Drugs mentioned

• AZD1775 (Adavosertib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm | Phase 2 | Status: COMPLETED | Results posted: 2023-09-13